SOURCE: Pluristem Life Systems

August 17, 2007 13:51 ET

Pluristem Life Systems to Present at the Noble Financial Two Double-0-Seven Small Cap Equity Conference

NEW YORK, NY--(Marketwire - August 17, 2007) - Pluristem Life Systems, Inc. (OTCBB: PLRS) (DAX: PJT), a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today it will present at the Noble Financial Equity Conference on Monday, August 20, 2007 at 12:00 PM ET at the Charleston Place Hotel in Charleston, South Carolina.

William R. Prather RPh, MD, Senior Vice President Corporate Development, will give a 25-minute presentation regarding Pluristem's history, technology and growth prospects. A question and answer session will follow the presentation and one-on-one meetings with investors will be held throughout the day.

The presentation with streaming video and PowerPoint presentation will be webcast live on Noble Financial's conference website at www.two-007.net. It will also be archived on Pluristem's website at www.pluristem.com. It is recommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access.

Pluristem Life Systems, Inc. (OTCBB: PLRS) is a biotechnology company dedicated to the commercialization of allogeneic stem cell therapy products for the treatment of several severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-I, targets a $2 billion market and intends to resolve the global shortfall of matched tissue for bone marrow transplantation by improving the engraftment of umbilical cord blood (UCB). Pluristem's products are derived from mesenchymal stem cells obtained from the placenta and expanded in the Company's proprietary PluriX™ 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors or cytokines. Pluristem believes the resultant expanded cells are multipotent and able to differentiate into a variety of different cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation.

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include that PLX-I cells shows promise in improving the engraftment of umbilical cord blood (UCB); has a potential market of $2 Billion; that the Pluristem's cells can potentially result in beneficial therapies for a number of serious diseases; and that our PLX cells may be the first allogeneic, off-the-shelf product to treat this serious disease. Factors that could prevent our forward-looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

Contact Information